lnp mrna service selection: what a formulation provider must report, and the characterisation that decides whether the particle delivers

Specifying the work

1. Lipid composition and its licence position. The ionisable lipid dominates delivery behaviour and is frequently proprietary and licensed. Establish which lipid is used, whether the composition is the provider's or yours, and what the licence terms are for your intended use, because that position travels with the programme.
2. The mixing process is the product. Particle size and uniformity come from how the streams are combined, and microfluidic and impingement approaches give different particles from identical inputs. Ask which process is used and whether the same process is available at the scale you may eventually need.
3. Encapsulation efficiency and payload. Unencapsulated RNA is degraded quickly and delivers nothing, so encapsulation efficiency and RNA content per particle should be measured and reported per batch rather than quoted as a process capability.
4. Size, dispersity and charge. Particle size distribution and dispersity affect biodistribution and reproducibility, and apparent surface charge affects tolerability. These should be reported per batch with the method, since they are the properties most likely to shift between runs.
5. Stability and storage. Establish the storage condition and the demonstrated stability period, including whether a cryoprotectant is used and how freeze and thaw affects the particle. A formulation that has not been stability tested at your storage condition is an unknown.

The RNA and the particle are one problem

Integrity of the RNA going in determines the material coming out, so a formulation service on poor RNA produces well-characterised particles containing degraded payload. Where the same provider supplies both, the boundary is at least clear; where they are separate, agree who tests the RNA on receipt.

Residual double-stranded RNA in the input carries through and continues to drive innate response after formulation. It is an input specification rather than something formulation can correct.

Research material and the regulated path

Research formulations are made without a quality system and cannot support a regulated application later. Ask early what a compliant route would require, because the process, the raw material grades and the testing all differ and none can be applied retrospectively.

Raw material grade in particular is a long-lead item, and programmes discovering that late lose months waiting for compliant lipid.

Common questions

What should an LNP formulation service report per batch?

Encapsulation efficiency, RNA content, particle size distribution and dispersity, apparent surface charge, and the storage condition with demonstrated stability, each with the method used.

Why does the mixing process matter?

Because identical lipids and RNA give different particles depending on how the streams are combined. Ask which process is used and whether it is available at the scale you may eventually need.

Does the ionisable lipid carry licence obligations?

Frequently. The ionisable lipid dominates delivery behaviour and is often proprietary, with terms that attach to your programme. Establish the position before committing to a composition.

Can research formulations support a regulated application?

No. Raw material grades, process and testing all differ and cannot be applied retrospectively. Ask what a compliant route requires early, since compliant lipid is a long-lead item.

Browse by service class

• Compare Gene synthesis on advertised prices